 | • レポートコード：QYR2104Z5872 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、VEGF/VEGFR阻害薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（チロシンキナーゼ阻害剤、モノクローナル抗体、その他）、用途別市場規模（腫瘍学、眼科、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・VEGF/VEGFR阻害薬の市場動向 ・企業の競争状況、市場シェア ・VEGF/VEGFR阻害薬の種類別市場規模（チロシンキナーゼ阻害剤、モノクローナル抗体、その他） ・VEGF/VEGFR阻害薬の用途別市場規模（腫瘍学、眼科、その他） ・VEGF/VEGFR阻害薬の北米市場規模2016-2027（アメリカ、カナダ） ・VEGF/VEGFR阻害薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・VEGF/VEGFR阻害薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・VEGF/VEGFR阻害薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・VEGF/VEGFR阻害薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Novartis AG、GlaxoSmithKline plc、Sanofi、AstraZeneca plc、Bristol-Myers-Squibb Company、Genentech, Inc. (Roche)、Merck & Co., Inc.、Bayer AG、Eli Lilly & Company） ・結論 |
Market Analysis and Insights: Global VEGF/VEGFR Inhibitor Drugs Market
The global VEGF/VEGFR Inhibitor Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global VEGF/VEGFR Inhibitor Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global VEGF/VEGFR Inhibitor Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global VEGF/VEGFR Inhibitor Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global VEGF/VEGFR Inhibitor Drugs market.
Global VEGF/VEGFR Inhibitor Drugs Scope and Market Size
VEGF/VEGFR Inhibitor Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global VEGF/VEGFR Inhibitor Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Oncology
Ophthalmology
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Novartis AG
GlaxoSmithKline plc
Sanofi
AstraZeneca plc
Bristol-Myers-Squibb Company
Genentech, Inc. (Roche)
Merck & Co., Inc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global VEGF/VEGFR Inhibitor Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tyrosine Kinase Inhibitors
1.2.3 Monoclonal Antibodies
1.2.4 Others
1.3 Market by Application
1.3.1 Global VEGF/VEGFR Inhibitor Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Ophthalmology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global VEGF/VEGFR Inhibitor Drugs Market Perspective (2016-2027)
2.2 VEGF/VEGFR Inhibitor Drugs Growth Trends by Regions
2.2.1 VEGF/VEGFR Inhibitor Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 VEGF/VEGFR Inhibitor Drugs Historic Market Share by Regions (2016-2021)
2.2.3 VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Regions (2022-2027)
2.3 VEGF/VEGFR Inhibitor Drugs Industry Dynamic
2.3.1 VEGF/VEGFR Inhibitor Drugs Market Trends
2.3.2 VEGF/VEGFR Inhibitor Drugs Market Drivers
2.3.3 VEGF/VEGFR Inhibitor Drugs Market Challenges
2.3.4 VEGF/VEGFR Inhibitor Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top VEGF/VEGFR Inhibitor Drugs Players by Revenue
3.1.1 Global Top VEGF/VEGFR Inhibitor Drugs Players by Revenue (2016-2021)
3.1.2 Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Players (2016-2021)
3.2 Global VEGF/VEGFR Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by VEGF/VEGFR Inhibitor Drugs Revenue
3.4 Global VEGF/VEGFR Inhibitor Drugs Market Concentration Ratio
3.4.1 Global VEGF/VEGFR Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by VEGF/VEGFR Inhibitor Drugs Revenue in 2020
3.5 VEGF/VEGFR Inhibitor Drugs Key Players Head office and Area Served
3.6 Key Players VEGF/VEGFR Inhibitor Drugs Product Solution and Service
3.7 Date of Enter into VEGF/VEGFR Inhibitor Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 VEGF/VEGFR Inhibitor Drugs Breakdown Data by Type
4.1 Global VEGF/VEGFR Inhibitor Drugs Historic Market Size by Type (2016-2021)
4.2 Global VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Type (2022-2027)
5 VEGF/VEGFR Inhibitor Drugs Breakdown Data by Application
5.1 Global VEGF/VEGFR Inhibitor Drugs Historic Market Size by Application (2016-2021)
5.2 Global VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America VEGF/VEGFR Inhibitor Drugs Market Size (2016-2027)
6.2 North America VEGF/VEGFR Inhibitor Drugs Market Size by Type
6.2.1 North America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021)
6.2.2 North America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027)
6.2.3 North America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2027)
6.3 North America VEGF/VEGFR Inhibitor Drugs Market Size by Application
6.3.1 North America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021)
6.3.2 North America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027)
6.3.3 North America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2027)
6.4 North America VEGF/VEGFR Inhibitor Drugs Market Size by Country
6.4.1 North America VEGF/VEGFR Inhibitor Drugs Market Size by Country (2016-2021)
6.4.2 North America VEGF/VEGFR Inhibitor Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe VEGF/VEGFR Inhibitor Drugs Market Size (2016-2027)
7.2 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Type
7.2.1 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021)
7.2.2 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027)
7.2.3 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2027)
7.3 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Application
7.3.1 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021)
7.3.2 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027)
7.3.3 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2027)
7.4 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Country
7.4.1 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Country (2016-2021)
7.4.2 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size (2016-2027)
8.2 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Type
8.2.1 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Application
8.3.1 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Region
8.4.1 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America VEGF/VEGFR Inhibitor Drugs Market Size (2016-2027)
9.2 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Type
9.2.1 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021)
9.2.2 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027)
9.2.3 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2027)
9.3 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Application
9.3.1 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021)
9.3.2 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027)
9.3.3 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2027)
9.4 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Country
9.4.1 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Country (2016-2021)
9.4.2 Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size (2016-2027)
10.2 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Type
10.2.1 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Application
10.3.1 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Country
10.4.1 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer VEGF/VEGFR Inhibitor Drugs Introduction
11.1.4 Pfizer Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG VEGF/VEGFR Inhibitor Drugs Introduction
11.2.4 Novartis AG Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.2.5 Novartis AG Recent Development
11.3 GlaxoSmithKline plc
11.3.1 GlaxoSmithKline plc Company Details
11.3.2 GlaxoSmithKline plc Business Overview
11.3.3 GlaxoSmithKline plc VEGF/VEGFR Inhibitor Drugs Introduction
11.3.4 GlaxoSmithKline plc Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.3.5 GlaxoSmithKline plc Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi VEGF/VEGFR Inhibitor Drugs Introduction
11.4.4 Sanofi Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.4.5 Sanofi Recent Development
11.5 AstraZeneca plc
11.5.1 AstraZeneca plc Company Details
11.5.2 AstraZeneca plc Business Overview
11.5.3 AstraZeneca plc VEGF/VEGFR Inhibitor Drugs Introduction
11.5.4 AstraZeneca plc Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.5.5 AstraZeneca plc Recent Development
11.6 Bristol-Myers-Squibb Company
11.6.1 Bristol-Myers-Squibb Company Company Details
11.6.2 Bristol-Myers-Squibb Company Business Overview
11.6.3 Bristol-Myers-Squibb Company VEGF/VEGFR Inhibitor Drugs Introduction
11.6.4 Bristol-Myers-Squibb Company Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.6.5 Bristol-Myers-Squibb Company Recent Development
11.7 Genentech, Inc. (Roche)
11.7.1 Genentech, Inc. (Roche) Company Details
11.7.2 Genentech, Inc. (Roche) Business Overview
11.7.3 Genentech, Inc. (Roche) VEGF/VEGFR Inhibitor Drugs Introduction
11.7.4 Genentech, Inc. (Roche) Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.7.5 Genentech, Inc. (Roche) Recent Development
11.8 Merck & Co., Inc.
11.8.1 Merck & Co., Inc. Company Details
11.8.2 Merck & Co., Inc. Business Overview
11.8.3 Merck & Co., Inc. VEGF/VEGFR Inhibitor Drugs Introduction
11.8.4 Merck & Co., Inc. Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.8.5 Merck & Co., Inc. Recent Development
11.9 Bayer AG
11.9.1 Bayer AG Company Details
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG VEGF/VEGFR Inhibitor Drugs Introduction
11.9.4 Bayer AG Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.9.5 Bayer AG Recent Development
11.10 Eli Lilly & Company
11.10.1 Eli Lilly & Company Company Details
11.10.2 Eli Lilly & Company Business Overview
11.10.3 Eli Lilly & Company VEGF/VEGFR Inhibitor Drugs Introduction
11.10.4 Eli Lilly & Company Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
11.10.5 Eli Lilly & Company Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global VEGF/VEGFR Inhibitor Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tyrosine Kinase Inhibitors
Table 3. Key Players of Monoclonal Antibodies
Table 4. Key Players of Others
Table 5. Global VEGF/VEGFR Inhibitor Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global VEGF/VEGFR Inhibitor Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global VEGF/VEGFR Inhibitor Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global VEGF/VEGFR Inhibitor Drugs Market Share by Regions (2016-2021)
Table 9. Global VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global VEGF/VEGFR Inhibitor Drugs Market Share by Regions (2022-2027)
Table 11. VEGF/VEGFR Inhibitor Drugs Market Trends
Table 12. VEGF/VEGFR Inhibitor Drugs Market Drivers
Table 13. VEGF/VEGFR Inhibitor Drugs Market Challenges
Table 14. VEGF/VEGFR Inhibitor Drugs Market Restraints
Table 15. Global VEGF/VEGFR Inhibitor Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global VEGF/VEGFR Inhibitor Drugs Market Share by Players (2016-2021)
Table 17. Global Top VEGF/VEGFR Inhibitor Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VEGF/VEGFR Inhibitor Drugs as of 2020)
Table 18. Ranking of Global Top VEGF/VEGFR Inhibitor Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by VEGF/VEGFR Inhibitor Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players VEGF/VEGFR Inhibitor Drugs Product Solution and Service
Table 22. Date of Enter into VEGF/VEGFR Inhibitor Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global VEGF/VEGFR Inhibitor Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America VEGF/VEGFR Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America VEGF/VEGFR Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe VEGF/VEGFR Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe VEGF/VEGFR Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America VEGF/VEGFR Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer VEGF/VEGFR Inhibitor Drugs Product
Table 65. Pfizer Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Novartis AG Company Details
Table 68. Novartis AG Business Overview
Table 69. Novartis AG VEGF/VEGFR Inhibitor Drugs Product
Table 70. Novartis AG Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 71. Novartis AG Recent Development
Table 72. GlaxoSmithKline plc Company Details
Table 73. GlaxoSmithKline plc Business Overview
Table 74. GlaxoSmithKline plc VEGF/VEGFR Inhibitor Drugs Product
Table 75. GlaxoSmithKline plc Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 76. GlaxoSmithKline plc Recent Development
Table 77. Sanofi Company Details
Table 78. Sanofi Business Overview
Table 79. Sanofi VEGF/VEGFR Inhibitor Drugs Product
Table 80. Sanofi Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 81. Sanofi Recent Development
Table 82. AstraZeneca plc Company Details
Table 83. AstraZeneca plc Business Overview
Table 84. AstraZeneca plc VEGF/VEGFR Inhibitor Drugs Product
Table 85. AstraZeneca plc Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 86. AstraZeneca plc Recent Development
Table 87. Bristol-Myers-Squibb Company Company Details
Table 88. Bristol-Myers-Squibb Company Business Overview
Table 89. Bristol-Myers-Squibb Company VEGF/VEGFR Inhibitor Drugs Product
Table 90. Bristol-Myers-Squibb Company Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 91. Bristol-Myers-Squibb Company Recent Development
Table 92. Genentech, Inc. (Roche) Company Details
Table 93. Genentech, Inc. (Roche) Business Overview
Table 94. Genentech, Inc. (Roche) VEGF/VEGFR Inhibitor Drugs Product
Table 95. Genentech, Inc. (Roche) Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 96. Genentech, Inc. (Roche) Recent Development
Table 97. Merck & Co., Inc. Company Details
Table 98. Merck & Co., Inc. Business Overview
Table 99. Merck & Co., Inc. Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 100. Merck & Co., Inc. Recent Development
Table 101. Bayer AG Company Details
Table 102. Bayer AG Business Overview
Table 103. Bayer AG VEGF/VEGFR Inhibitor Drugs Product
Table 104. Bayer AG Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 105. Bayer AG Recent Development
Table 106. Eli Lilly & Company Company Details
Table 107. Eli Lilly & Company Business Overview
Table 108. Eli Lilly & Company VEGF/VEGFR Inhibitor Drugs Product
Table 109. Eli Lilly & Company Revenue in VEGF/VEGFR Inhibitor Drugs Business (2016-2021) & (US$ Million)
Table 110. Eli Lilly & Company Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global VEGF/VEGFR Inhibitor Drugs Market Share by Type: 2020 VS 2027
Figure 2. Tyrosine Kinase Inhibitors Features
Figure 3. Monoclonal Antibodies Features
Figure 4. Others Features
Figure 5. Global VEGF/VEGFR Inhibitor Drugs Market Share by Application: 2020 VS 2027
Figure 6. Oncology Case Studies
Figure 7. Ophthalmology Case Studies
Figure 8. Others Case Studies
Figure 9. VEGF/VEGFR Inhibitor Drugs Report Years Considered
Figure 10. Global VEGF/VEGFR Inhibitor Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global VEGF/VEGFR Inhibitor Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global VEGF/VEGFR Inhibitor Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global VEGF/VEGFR Inhibitor Drugs Market Share by Regions (2022-2027)
Figure 14. Global VEGF/VEGFR Inhibitor Drugs Market Share by Players in 2020
Figure 15. Global Top VEGF/VEGFR Inhibitor Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VEGF/VEGFR Inhibitor Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by VEGF/VEGFR Inhibitor Drugs Revenue in 2020
Figure 17. Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America VEGF/VEGFR Inhibitor Drugs Market Share by Type (2016-2027)
Figure 21. North America VEGF/VEGFR Inhibitor Drugs Market Share by Application (2016-2027)
Figure 22. North America VEGF/VEGFR Inhibitor Drugs Market Share by Country (2016-2027)
Figure 23. United States VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe VEGF/VEGFR Inhibitor Drugs Market Share by Type (2016-2027)
Figure 27. Europe VEGF/VEGFR Inhibitor Drugs Market Share by Application (2016-2027)
Figure 28. Europe VEGF/VEGFR Inhibitor Drugs Market Share by Country (2016-2027)
Figure 29. Germany VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Share by Application (2016-2027)
Figure 38. Asia-Pacific VEGF/VEGFR Inhibitor Drugs Market Share by Region (2016-2027)
Figure 39. China VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America VEGF/VEGFR Inhibitor Drugs Market Share by Type (2016-2027)
Figure 47. Latin America VEGF/VEGFR Inhibitor Drugs Market Share by Application (2016-2027)
Figure 48. Latin America VEGF/VEGFR Inhibitor Drugs Market Share by Country (2016-2027)
Figure 49. Mexico VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Share by Application (2016-2027)
Figure 54. Middle East & Africa VEGF/VEGFR Inhibitor Drugs Market Share by Country (2016-2027)
Figure 55. Turkey VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Pfizer Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 59. Novartis AG Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 60. GlaxoSmithKline plc Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 61. Sanofi Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 62. AstraZeneca plc Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 63. Bristol-Myers-Squibb Company Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 64. Genentech, Inc. (Roche) Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 65. Merck & Co., Inc. Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 66. Bayer AG Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 67. Eli Lilly & Company Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
世界の抗血管内皮増殖因子（抗VEGF）薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market The global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With in…- 世界の抗血管内皮増殖因子（抗VEGF）薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market The global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With in…
- 世界のサイクリン依存性キナーゼ阻害剤市場規模・現状・予測（2021年-2027年） Cyclin-dependent kinase inhibitor function as tumor suppressor proteins by inhibiting the enzyme cyclin-dependent kinase. The enzyme cyclin-dependent kinase controls cell cycle progression, transcription, mRNA processing, and differentiation. Cyclin-dependent kinase inhibitor arrest cell cycle at th…
- 世界のブルトン型チロシンキナーゼ（BTK）阻害剤市場規模・現状・予測（2021年-2027年） Bruton's tyrosine kinase (Btk), a member of the non-receptor tyrosine kinase Tec family, is a key signaling enzyme expressed in all hematopoietic cell types except T lymphocytes and natural killer cells.Btk plays a crucial role in stimulating B cell signaling pathways that connect the cell surface B…
- 世界の血漿プロテアーゼC1阻害剤治療市場規模・現状・予測（2021年-2027年） This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising p…